PanopticAI, a leading innovator in remote patient monitoring, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its contactless vital signs monitoring software. The PanopticAI Vital Signs app is the first FDA-cleared mobile application for contactless pulse rate measurement using the built-in camera of iPhones and iPads. This also distinguishes PanopticAI as the first Hong Kong-based company to achieve FDA clearance for a Software as a Medical Device (SaMD).
PanopticAI’s technology leverages proprietary remote photoplethysmography (rPPG) algorithms to transform readily available smartphones and tablets into medical-grade vital sign monitors. Advanced AI and signal processing techniques are used to analyze subtle color changes in the skin captured by the device’s camera, accurately measuring vital signs like pulse rate in just 30 seconds.
